Stevan Shaw
Overview
Explore the profile of Stevan Shaw including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
628
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baraliakos X, de Jongh J, Poddubnyy D, Zwezerijnen G, Hemke R, Glatt S, et al.
Ther Adv Musculoskelet Dis
. 2024 Dec;
16:1759720X241293944.
PMID: 39620046
Background: The efficacy and safety of bimekizumab (BKZ), an inhibitor of interleukin (IL)-17F in addition to IL-17A, has been established in axial spondyloarthritis (axSpA). Early assessment of new bone formation...
2.
Rastrick J, Edwards H, Ferecsko A, Le Friec G, Manghera A, Page M, et al.
Br J Dermatol
. 2024 Nov;
PMID: 39531733
Background: Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory skin disease associated with significant comorbidities and poor quality of life. Despite uncertainty about pathways driving inflammation in HS lesions, the...
3.
Adams R, Bunick C, Lawson A, Gomez B, Shaw S
J Invest Dermatol
. 2024 Apr;
144(11):2581-2583.e2.
PMID: 38631666
No abstract available.
4.
Tanaka Y, Shaw S
Expert Rev Clin Immunol
. 2023 Nov;
20(2):155-168.
PMID: 37909894
Introduction: Interleukin (IL)-17A and IL-17F have overlapping roles in pro-inflammatory signaling and have been implicated in the pathogenesis of psoriatic disease. Bimekizumab is the first human monoclonal antibody to selectively...
5.
Cole S, Manghera A, Burns L, Barrett J, Yager N, Rhys H, et al.
J Allergy Clin Immunol
. 2023 May;
152(3):783-798.
PMID: 37244461
Background: IL-17A plays a pivotal pathogenic role in several immune-mediated inflammatory diseases. Despite sharing 50% sequence homology with IL-17A, the role of IL-17F remains less clear. Clinical findings suggest that...
6.
Glatt S, Jemec G, Forman S, Sayed C, Schmieder G, Weisman J, et al.
JAMA Dermatol
. 2021 Aug;
157(11):1279-1288.
PMID: 34406364
Importance: Hidradenitis suppurativa (HS) is a chronic inflammatory disease with a high burden for patients and limited existing therapeutic options. Objective: To evaluate the efficacy and safety of bimekizumab, a...
7.
Cole S, Murray J, Simpson C, Okoye R, Tyson K, Griffiths M, et al.
Front Immunol
. 2020 Dec;
11:585134.
PMID: 33329560
IL-23 is considered a critical regulator of IL-17 in Th17 cells; however, its requirement for inducing IL-17 production in other human immune subsets remains incompletely understood. Mucosal associated invariant T...
8.
Adams R, Maroof A, Baker T, Lawson A, Oliver R, Paveley R, et al.
Front Immunol
. 2020 Sep;
11:1894.
PMID: 32973785
Interleukin (IL)-17A is a key driver of inflammation and the principal target of anti-IL-17 therapeutic monoclonal antibodies. IL-17A, and its structurally similar family member IL-17F, have been shown to be...
9.
Shah M, Maroof A, Gikas P, Mittal G, Keen R, Baeten D, et al.
RMD Open
. 2020 Jul;
6(2).
PMID: 32723833
Objectives: Interleukin (IL)-17 signalling has been shown to be a key regulator of disease in ankylosing spondylitis (AS) with several IL-17 blockers currently clinically approved. Despite this, the role of...
10.
Chen S, Paveley R, Kraal L, Sritharan L, Stevens E, Dedi N, et al.
J Autoimmun
. 2020 May;
111:102435.
PMID: 32360069
The delta isoform of phosphoinositide 3-kinase (PI3Kδ) regulates various lymphocyte functions. Considering the key pro-inflammatory role of IL-17A and IL-17F cytokines in psoriasis and spondyloarthritis (SpA), we investigated the potential...